CDR132L is an antisense RNA therapy that inhibits MiR-132. It is developed by Cardior Pharmaceuticals to treat heart failure.[1][2][3]
References[edit]
- ^ Batkai, Sandor; Genschel, Celina; Viereck, Janika; Rump, Steffen; Bär, Christian; Borchert, Tobias; Traxler, Denise; Riesenhuber, Martin; Spannbauer, Andreas; Lukovic, Dominika; Zlabinger, Katrin; Hašimbegović, Ena; Winkler, Johannes; Garamvölgyi, Rita; Neitzel, Sonja; Gyöngyösi, Mariann; Thum, Thomas (7 January 2021). "CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure". European Heart Journal. 42 (2): 192–201. doi:10.1093/eurheartj/ehaa791. PMC 7813625.
- ^ Taubel, Jorg; Hauke, Wilfried; Rump, Steffen; Viereck, Janika; Batkai, Sandor; Jenny, Poetzsch; Laura, Rode; Weigt, Henning; Genschel, Celina; Lorch, Ulrike; Theek, Carmen; Levin, Arthur A; Bauersachs, Johann B; Solomon, Scott D; Thum, Thomas (3 September 2021). "Abstract 114: Safety And Efficacy Of CDR132L, A Novel Antisense Therapeutic Which Targets MicroRNA-132 In Heart Failure Patients". Circulation Research. 129 (Suppl_1). doi:10.1161/res.129.suppl_1.114.
- ^ Täubel, Jörg; Hauke, Wilfried; Rump, Steffen; Viereck, Janika; Batkai, Sandor; Poetzsch, Jenny; Rode, Laura; Weigt, Henning; Genschel, Celina; Lorch, Ulrike; Theek, Carmen; Levin, Arthur A; Bauersachs, Johann; Solomon, Scott D; Thum, Thomas (11 November 2020). "Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study". European Heart Journal. 42 (2): 178–188. doi:10.1093/eurheartj/ehaa898. ISSN 0195-668X. PMC 7954267.